Gennova Biopharmaceuticals, a subsidiary of Pune-headquartered Emcure Pharmaceuticals, is not only developing India’s first indigenous messenger ribonucleic acid (mRNA) Cov­id-19 vaccine, but also plans to leverage the platform to develop vaccines for the Zika virus, herpes zoster (shingles), and tuberculosis (TB). “The mRNA platform is disease-agnostic.

Leave a Reply

Your email address will not be published. Required fields are marked *

Gennova Biopharmaceuticals, a subsidiary of Pune-headquartered Emcure Pharmaceuticals, is not only developing India’s first indigenous messenger ribonucleic acid (mRNA) Cov­id-19 vaccine, but also plans to leverage the platform to develop vaccines for the Zika virus, herpes zoster (shingles), and tuberculosis (TB). “The mRNA platform is disease-agnostic.

Leave a Reply

Your email address will not be published. Required fields are marked *